DUBLIN--(BUSINESS WIRE)--The "Single-use Bioreactor Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The Global Single-use Bioreactor market is expected to witness a CAGR of 15.5% during the forecast period.
Certain factors that are driving the market growth include rapid adoption of Single-use Technologies (SUTs) by the industry, cost-effectiveness and lower downtime, and launch of new products.
The inclination of the industry to use single-use bioreactors is currently being influenced by the criticality of the step, the value of the product, and the time for product development and production. These single-use bioreactors are in high demand from the medical sector. These reactors are thus adopted by pharmaceutical companies to manufacture drugs without any negotiations on their quality. One of the biggest advantages of the adoption of singleuse bioreactors is found to be flexibility. The increasing trend towards multidrug facilities demands the production of different drugs using the same facility, with minimum time and cost.
However, at some point, the capital investment is found to be exceeded by the repetitive cost for plastic ware and single-use consumables. So, although, fixed stainless steel equipment have high upfront costs in terms of installation and maintenance, the regular recurring expenses for single-use bioreactors (SUBs) is found to be higher. In addition, the high costs may be involved in proper waste management of the vast amounts of disposables.
Key Market Trends
Single-use Bioreactor Systems are Expected to Hold Significant Market Share in the Type of Product Segment
In recent years, the single-use bioreactors have been increasingly adopted in the modern biopharmaceutical processes. This is primarily owing to its unique ability to enhance flexibility, reduce investment, and limit operational costs. For industrial advantages, the single-use bioreactors are the more attractive options for multiproduct facilities with up to 6,000 liters.
The applications of single-use bioreactors are wide from academic to commercial-scale laboratories in drug discovery, pharmaceutical, environmental, and life science for the development of vaccines, antibodies, cell culture, biofuel manufacturing, and more.
The recent years have observed companies specializing in the development of single-use bioreactor, which has modified the existing glass bioreactor to a single-use bioreactor in seconds. Distek Inc. also developed a benchtop SUB system for mammalian cell growth and recombinant protein production.
North America Dominates the Market and Expected to do Same in the Forecasted Period
The pharmaceuticals and hi-tech product makers announced multimillion-dollar investments to expand manufacturing capabilities, which is a positive aspect for the market studied. For example, Abzena, a pharmaceutical company, began the installation of a new 500L BIOSTAT STR, single-use bioreactor, as part of a series of significant investments in its San Diego process development and manufacturing operations.
Partnerships between industries and academic institutions have witnessed a significant rise, over recent years. Such collaborations plan to leverage the research and development resources of various universities, in the region, with the commercial therapeutics and vaccine development and manufacturing capabilities of the CMOs.
Competitive Landscape
The global Single-use Bioreactor market is highly competitive and consists of a number of major players. Companies like ABEC Inc, Celltainer, Distek Inc., Eppendorf AG, GE Healthcare, Merck KGaA, OmniBRx Biotechnologies, Pall Corporation, Sartorius AG, Thermo Fisher Scientific, among others, hold the substantial market share in the Single-use Bioreactor market.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapid Adoption of Single-use Technologies (SUTs) by the Industry
4.2.2 Cost Effectiveness and Lower Downtime
4.2.3 Launch of New Products
4.3 Market Restraints
4.3.1 High Regular Recurring Expenses
4.3.2 Issues with Meeting the Standards of Good Manufacturing Practices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type of Product
5.1.1 Single-use Bioreactor Systems
5.1.2 Media Bags
5.1.3 Filtration Assemblies
5.1.4 Other Products
5.2 Cell Type
5.2.1 Mammalian Cell
5.2.2 Bacteria
5.2.3 Yeast
5.2.4 Other Cell Types
5.3 Molecule Type
5.3.1 Vaccines
5.3.2 Monoclonal Antibodies
5.3.3 Stem Cells
5.3.4 Recombinant Proteins
5.3.5 Other Molecule Types
5.4 End-user
5.4.1 Pharmaceutical and Biopharmaceutical Industries
5.4.2 Contract Research Organizations (CRO)
5.4.3 Other End-users
5.5 Geography
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 UK
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ABEC Inc.
6.1.2 Celltainer
6.1.3 Distek Inc.
6.1.4 Eppendorf AG
6.1.5 GE Healthcare
6.1.6 Merck KGaA
6.1.7 OmniBRx Biotechnologies
6.1.8 Pall Corporation
6.1.9 Sartorius AG
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/fng9ot
